Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nevanimibe - Millendo Therapeutics

Drug Profile

Nevanimibe - Millendo Therapeutics

Alternative Names: ATR-101

Latest Information Update: 15 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan
  • Developer Millendo Therapeutics
  • Class Antineoplastics; Methylamines; Phenols; Small molecules; Urea compounds
  • Mechanism of Action Acetyl-CoA C-acetyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cushing syndrome; Congenital adrenal hyperplasia; Adrenocortical carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Adrenocortical carcinoma; Congenital adrenal hyperplasia; Cushing syndrome

Most Recent Events

  • 30 Apr 2021 Nevanimibe is no longer licensed to Millendo Therapeutics worldwide
  • 14 Jul 2020 Discontinued - Phase-I for Adrenocortical carcinoma (Late-stage disease) in USA, Germany (PO) due to unfavourable data from an interim analysis of the phase IIb ATR-101-202 trial in Congenital adrenal hyperplasia (NCT03669549)
  • 14 Jul 2020 Discontinued - Phase-II for Congenital adrenal hyperplasia (In the elderly, Treatment-experienced, In adults) in Czech Republic, Israel, France, Brazil, Spain (PO) due to unfavourable data from an interim analysis of the phase IIb ATR-101-202 trial in Congenital adrenal hyperplasia (NCT03669549)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top